Table 2.

Effect of CCM111 on the serum parameters in the CCl₄-treated mice.

Groups	Activity
	GOT (U/L)	GPT (U/L)	TG (mg/dl)	TCHO (mg/dl)
Control	89.33 ± 47.9	26.83 ± 8.52*	213.50 ± 46.37	199.17 ± 40.51
CCl4	323.83 ± 188.09#	262.50 ± 199.21#	232.17 ± 74.99	133.83 ± 26.12#
SIL	70.60 ± 37.87*	54.60 ± 52.64*	202.50 ± 43.54	125.50 ± 32.46
L-CCM111	71.33 ± 9.93*	71.33 ± 9.93*	176.67 ± 57.69	109.83 ± 19.55
H-CCM111	53.00 ± 13.88*	53.00 ± 13.88*	191.00 ± 39.22	125.20 ± 28.60

CCl₄ was intraperitoneally given at a dose of 40% twice per week for 8 weeks to each group except control group. The data represent the mean ± SD of six mice.

^#Significantly different from the control group, P < 0.05.

^*Significantly different from the group treated with CCl₄ alone, P < 0.05.